Reuters logo
BRIEF-AstraZeneca Duaklir improves lung function in COPD patients
September 7, 2017 / 6:16 AM / 2 months ago

BRIEF-AstraZeneca Duaklir improves lung function in COPD patients

Sept 7 (Reuters) - AstraZeneca Plc

* AZ DUAKLIR IMPROVES LUNG FUNCTION IN COPD PATIENTS

* PHASE III AMPLIFY TRIAL DEMONSTRATED A STATISTICALLY- SIGNIFICANT IMPROVEMENT IN LUNG FUNCTION IN PATIENTS WITH COPD

* STUDY ACHIEVED PRIMARY ENDPOINTS TO SUPPORT A NEW DRUG APPLICATION (NDA) SUBMISSION

* EXPECTED TO SUBMIT AN NDA DURING H1 2018 TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR DUAKLIR, BASED ON AMPLIFY DATA Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below